Blood

Continuous Renal Replacement Therapy (CRRT) - Global Market Trajectory & Analytics to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022 - 10:22am
Health, General Health, Hemofiltration, Ageing, Population, Investment, Hypotension, Traction, Incidence, Prevalence, Ultrafiltration, Hospital, Acute kidney injury, Renal replacement therapy, Degenerative disease, Blood, Convection, Patient, AKI, COVID-19, Diffusion, Water, CAGR, Kidney, RRT, Growth, CRRT, Pharmaceutical industry, Medical imaging

The "Continuous Renal Replacement Therapy (CRRT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Renal Replacement Therapy (CRRT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The United States represents the largest regional market for Continuous Renal Replacement Therapy (CRRT), and is projected to reach US$422.4 Million by 2026.
  • The global Continuous Renal Replacement Therapy (CRRT) market is expected to increase rapidly in future, driven by rising incidence of acute kidney injury (AKI).
  • Europe and the United States dominate the Continuous Renal Replacement Therapy market, driven by the fast growing aging population and increasing acute kidney injury cases.

WellSky® Submits Comment Letter to Centers for Medicare & Medicaid Services Regarding Home Health Proposed Payment Rule

Retrieved on: 
Wednesday, August 17, 2022 - 7:25pm
Health, Healthcare Reform, Health Technology, Public Policy, Government, Health Insurance, Machine learning, Home health, Telephone, Movement, Blood, Medicare Payment Advisory Commission, Travel, Risk, Observation, Comment, Medicare, Industry, Technology, Growth, ALOS, Telecommunication, UnityPoint Health, Behavior, Congress, Caregiver, Government, Health, Report, Patient, Hospital, COVID-19, CMS, PPS, Education, Visiting Nurse Service of New York, Home, JAMA Internal Medicine, Asmara, HH, Confusion, Nursing care plan, Software, Collection, Time, BNA, Nursing, Demography, Overalls, PHE, SNF, Organization, Health insurance, Life insurance, Medicine, Mobile phone

As a result, Medicare beneficiaries will likely have access to fewer home health options and services.

Key Points: 
  • As a result, Medicare beneficiaries will likely have access to fewer home health options and services.
  • In addition to the impact of the Proposed Rule on home health providers and, therefore, Medicare beneficiaries, it is important to note the downstream consequences for overall Medicare spending.
  • Under PDGM, the volume of therapy is not a measure within the payment model that affects the level of payment.
  • Our next-generation software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum.

FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

Retrieved on: 
Wednesday, August 17, 2022 - 6:39pm
FDA, Liver, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vomiting, Nausea, Cough, Food, Multimedia, Public health, Risk, Oxygen, Office of Inspector General, U.S. Department of Health and Human Services, Hair, Dizziness, Cancer, Animal, Cosmetics, Achievement, Blood, Diarrhea, Rash, Human services, Abdominal pain, Fever, Patient, Beta thalassemia, Hair loss, Fatigue, Cell, Bleeding, Center for Biologics Evaluation and Research, Center, Iron, Mucositis, Itch, Pigmentation disorder, Vaccine, Safety, Febrile neutropenia, Smokeless tobacco, Priority review, Research, Headache, Appetite, Weakness, Lymphatic system, Nosebleed, Heart, Thalassemia, Lists of diseases, China Biologic Products, Dietary supplement, Thrombocytopenia, Adult, Disease, Constipation, Pharmaceutical industry, Betibeglogene autotemcel

SILVER SPRING, Md., Aug. 17, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Key Points: 
  • SILVER SPRING, Md., Aug. 17, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
  • The reduced levels of red blood cells can lead to a number of health issues including dizziness, weakness, fatigue, bone abnormalities and more serious complications.
  • Transfusion-dependent beta-thalassemia, the most severe form of the condition, generally requires life-long red blood cell transfusions as the standard course of treatment.
  • The safety and effectiveness of Zynteglo were established in two multicenter clinical studies that included adult and pediatric patients with beta-thalassemia requiring regular transfusions.

Cilicon Partners with Vape-Jet to Offer an Intelligent and Integrated Vaporizer Solution

Retrieved on: 
Wednesday, August 17, 2022 - 4:15pm
Industry, GLOBE, Technology, Intelligence, Blood, Integration, Cannabis, Partnership, Safety, Â, Herbal cigarette, Culture, Solution, Time, Orientation, 3D printing

Through the partnership, the companies will work smarter by working together, addressing customers needs with an intelligent and integrated product solution.

Key Points: 
  • Through the partnership, the companies will work smarter by working together, addressing customers needs with an intelligent and integrated product solution.
  • As a one-stop solution provider, Vape-Jet and Cilicon offer guaranteed hardware compatibility and standardized operating procedures, all under the unified mission to elevate the customer's vape cartridge production.
  • The Intelligent and Integrated Vape-Filling Solution by Cilicon and Vape-Jet is now available worldwide.
  • Cilicon derives a game-changing Cilicon Designed platform from generating diverse cannabis vaporizer options available for increasing customer brand competitiveness from the crowd.

TerraPro Solutions, Better Business Bureau (BBB) Serving the Pacific Southwest, and Mulligan Funding, Team Up with San Diego Blood Bank for Life-Saving Donation Drive

Retrieved on: 
Wednesday, August 17, 2022 - 3:00pm
Wind, Organic, CEO, Pacific Ocean, Better Business Bureau, GWS, Trauma, Compliance, Blood, BBB, Marketing, Patient, Instagram, Small business, Twitter, SAN, Acquisition, International Association, Singapore Cord Blood Bank, Blood bank, Health, LinkedIn, U.S. Army Community Relations, Hospital, Pacific Southwest

SAN DIEGO, Aug. 17, 2022 /PRNewswire-PRWeb/ -- The life-saving work of the San Diego Blood Bank serves hospitals in Southern California, including trauma centers and neonatal intensive care units. A single donation can help save up to three lives. As Southern California continues to grow, the need to expand blood collections in the region is critical. Every donation saves lives.

Key Points: 
  • The San Diego Blood Drive will be held on Friday, September 9th, from 10:00am to 4:00pm at the Better Business Bureau, 4747 Viewridge Ave., San Diego, CA 92123.
  • SAN DIEGO, Aug. 17, 2022 /PRNewswire-PRWeb/ -- The life-saving work of the San Diego Blood Bank serves hospitals in Southern California, including trauma centers and neonatal intensive care units.
  • "We are extremely grateful that TerraPro Solutions, BBB Pacific Southwest's San Diego Campus and Mulligan Funding have joined forces to host a life-saving blood drive."
  • San Diego Blood Bank is a 501(c)(3) nonprofit organization also operating as Southern California Blood Bank.

NanoDx and SkyWater Announce First Commercially Ready Nano Biosensor to Yield Protein Response

Retrieved on: 
Wednesday, August 17, 2022 - 2:05pm
Semiconductor, Electronic Design Automation, Aerospace, Manufacturing, Technology, Nanotechnology, Oncology, General Health, Biometrics, Infectious Diseases, Other Manufacturing, Other Technology, Biotechnology, Software, Health, Engineering, FDA, Antibody, Point-of-care testing, System, Roic, Biomarker, Nanosensor, IBM, CEO, Forward-looking statement, Technology, IOT, Private Securities Litigation Reform Act, SEC, Disease, Saliva, CMOS, Health, Blood, Review, Stroke, Company, Infection, Form 10-K, Architecture, SkyWater Technology, NASDAQ, IBM cloud computing, Research, Sepsis, MEMS, Nanowire, FTI, IBM Research, COVID-19, FTI Consulting, TBI, ICS, Annual report, Nano, Traumatic brain injury, AGC Aerospace & Defense, Medical imaging, Medical device

NanoDx, Inc., a developer of breakthrough point-of-care diagnostic solutions and SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced the first commercially ready nano biosensor to yield a protein response.

Key Points: 
  • NanoDx, Inc., a developer of breakthrough point-of-care diagnostic solutions and SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced the first commercially ready nano biosensor to yield a protein response.
  • Building upon the licensed IBM Research technology, NanoDx partnered with SkyWater to co-develop and produce the nanoscale sensors.
  • Subsequently, NanoDx engaged with FTI Consulting to further transition the organization from product development to preparation for commercialization.
  • NanoDx is a privately-held, U.S.-based medical device company developing rapid near-patient, point-of-care testing in-vitro diagnostic products on its proprietary nanowire biosensor platform.

Blood Collection Market size worth $ 13.2 Billion, Globally, by 2030 at 5.1% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, August 17, 2022 - 2:15pm
Lists of diseases, Injury, Death, Qiagen, Growth, USD, Blood, GE Healthcare, Trauma, Patient, Company, Acquisition, BD, Medtronic, GE Ventures, Conditional sentence, Partnership, Accident, CAGR, Geography, Research, Dickinson, BD (company), Hospital, Pharmacy, Health, Market research, Becton, Medical device, Pharmaceutical industry, Method

JERSEY CITY, N.J., Aug. 17, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Blood Collection Market" By Product (Blood Collection Tubes, Blood Bags), By Method (Manual Blood Collection, Automated Blood Collection), By End User (Hospitals And Pathology Laboratories, Blood Banks), and By Geography. According to Verified Market Research, the Blood Collection Market size was valued at USD 8.9 Billion in 2021 and is projected to reach USD 13.2 Billion by 2030, growing at a CAGR of 5.1% from 2022 to 2030. 

Key Points: 
  • JERSEY CITY, N.J., Aug. 17, 2022 /PRNewswire/ --Verified Market Research recently published a report, " Blood Collection Market " By Product (Blood Collection Tubes, Blood Bags), By Method (Manual Blood Collection, Automated Blood Collection), By End User (Hospitals And Pathology Laboratories, Blood Banks), and By Geography.
  • According to Verified Market Research, the Blood Collection Market size was valued at USD 8.9 Billion in 2021 and is projected to reach USD 13.2 Billion by 2030, growing at a CAGR of 5.1% from 2022 to 2030.
  • The increasing number of chronic diseases globally, are driving the expansion of the worldwide Blood Collection Market.
  • Verified Market Research has segmented the Global Blood Collection Market On the basis of Product, Method, End User, and Geography.

Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Retrieved on: 
Wednesday, August 17, 2022 - 2:00pm
Research, Technology, Genetics, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Rubius, Machine learning, Hematology, Single-cell analysis, CEO, Algorithm, Ecosystem, Growth, B cell, Investment, CD34, Disease, Differentiable function, Flagship, David Berry (inventor), Tissue, Knowledge, Method, Life, Blood, Lists of diseases, MRNA, NP-hardness, DNA, Cell, Bone marrow, Data, Conference on Neural Information Processing Systems, RNA, NASDAQ, Biology, Doctor of Pharmacy, Respiratory disease, HSPC, Protein, SANA, Yale University, Flagship Pioneering, Time, Health, Adult, Mobile phone, Vaccine, Medical imaging, Kaggle, Zasmidium cellare

This time course will be used to power a competition to develop algorithms that learn the underlying relationships between DNA, RNA, and protein modalities across time.

Key Points: 
  • This time course will be used to power a competition to develop algorithms that learn the underlying relationships between DNA, RNA, and protein modalities across time.
  • Solving this open problem will help elucidate complex regulatory processes that are the foundation for cell differentiation in health and disease.
  • New machine learning algorithms are needed to learn the rules that govern complex cell regulatory processes so we can predict how cell state changes over time.
  • This translation of knowledge across disciplines is expected to drive more powerful algorithms to learn fundamental rules of biology.

OUTSET MEDICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Outset Medical, Inc. - OM

Retrieved on: 
Wednesday, August 17, 2022 - 3:54am
FDA, FREE, Dialysis, GLOBE, LLC, Blood, Patient, Lists of schools in England, Company, Lawyer, Water, District court, Nasdaq, Kidney failure, News, Outset Media, Medical device, Private investigator, Security (finance)

This action is pending in the United States District Court for the Northern District of California.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of California.
  • Outset investors should visit us at https://claimsfiler.com/cases/nasdaq-om/ or call toll-free (844) 367-9658.
  • CareDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • Outset and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

Vuzix M400 Smart Glasses Begin Use Case in Japan for Ambulance Emergency Medical Care

Retrieved on: 
Tuesday, August 16, 2022 - 6:00pm
U.S. Securities and Exchange Commission, Vital signs, Risk, Juntendo University, Emergency, Forward-looking statement, Technology, IP, Facebook, Blood transfusion, M400, Hospital, ECG, Smartglasses, Research, Communication, Emergency medical technician, Nursing, Degenerative disease, Patient, Company, Twitter, Blood, Private Securities Litigation Reform Act, CES, NASDAQ, Intention, News, Thrombolysis, AE, Wireless, Augmented reality, Ambulance, Consumer Electronics Show, Solution, MD, AR, Pharmaceutical industry, Health insurance, Vuzix

In this trial, emergency medical technicians (EMTs) are using Vuzix M400 smart glasses to convey medical information from the ambulance to the hospital from the moment of patient engagement to their delivery to the hospital.

Key Points: 
  • In this trial, emergency medical technicians (EMTs) are using Vuzix M400 smart glasses to convey medical information from the ambulance to the hospital from the moment of patient engagement to their delivery to the hospital.
  • Additionally, in-hospital doctors can better instruct accurate in-transit emergency treatment (blood transfusion, surgery, thrombolytic therapy, intravascular treatment, etc.)
  • Currently, Vuzix smart glasses are being used by select ambulances under the jurisdiction of the Shunto Izu Fire Department.
  • Vuzix is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets.